What is thymosin alpha-1?

Thymosin alpha-1, known by the international name thymalfasin, is a peptide that modulates immune function. Unlike most compounds we cover it is a licensed medicine in a number of countries, used classically in chronic hepatitis B, and it has been studied extensively in critical care.

Is thymosin alpha-1 FDA-approved?

No. It is approved in a number of other countries, which is why you will see it described flatly as an approved medicine. Both statements can be true at once, and which one applies to you depends on where you are - this is the clearest example on the site of why we record legal status per country rather than as a single fact.

Does thymosin alpha-1 work?

For the marketed use - general immune support in healthy people - nobody has tested it. In the settings it has been tested, the most recent and largest trial is negative: a multicentre randomised trial published in the BMJ in 2025 found no clear evidence that it reduces 28-day mortality in adults with sepsis.

Who were the trials actually run in?

Patients with sepsis, with predicted severe acute necrotising pancreatitis, and with chronic hepatitis - people who were seriously unwell, in hospital, under supervision. That is a long way from someone taking it to catch fewer colds.

Is buying thymosin alpha-1 online the same product?

No. A licensed version exists in some countries, made to pharmaceutical standards. Research-chemical vendors sell the same molecule name with none of that assurance, and importing an unapproved medicine has its own legal consequences depending on where you live.

Research peptides

Thymosin Alpha-1: A Real Medicine, Tested in People Far Sicker Than You

64 randomised trials and approvals outside the US. The newest and largest, in the BMJ, found no clear survival benefit. None of it studied healthy people.

Written bySebastian Hunter, Founder and Editor

Published August 23, 2026

Start here

Plain English

Thymosin alpha-1 is an approved medicine in a number of countries, though not in the United States, and it has a large clinical trial record. Those trials are in sepsis, pancreatitis and hepatitis - hospital patients, not healthy adults. The newest and largest, published in the BMJ in 2025, found no clear survival benefit.

864 papers and 64 randomised trials - the best-evidenced compound in this market.
The 2025 BMJ sepsis trial found no clear mortality benefit.
Approved in some countries, not by the FDA. Where you are changes what it is.

Thymosin alpha-1 has more clinical evidence behind it than anything else we cover in the research-chemical market. Eight hundred and sixty-four papers. Sixty-four randomised controlled trials. An international non-proprietary name, thymalfasin, and marketing approval in a number of countries.

It is a real medicine. It has also never been tested for the thing it is sold for online, and its newest and largest trial is negative.

Where the trials were run

Thymosin alpha-1 randomised trials cited here, by setting

Sepsis, critical careincluding the 2025 BMJ trial
2
Severe acute pancreatitispredicted severe necrotising
1
Chronic hepatitiswith interferon alfa
1
Healthy adults, immune supportthe marketed use
0

The clinical programme is in hospital medicine: sepsis, severe pancreatitis, chronic hepatitis. Nobody has run a randomised trial of thymosin alpha-1 for general immune support in healthy adults, which is what the online market sells it for.

The newest trial, and what it found

TESTS was a multicentre randomised controlled trial asking whether thymosin alpha-1 reduces mortality in adults with sepsis, published in the BMJ in 2025 Wu 2025 - Wu J, Pei F, Zhou L et al. The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025;388:e082583. (opens PubMed in a new tab). Its primary outcome was 28-day all-cause mortality.

Its conclusion, in its own words: the trial “found no clear evidence to suggest that thymosin α1 decreases 28 day all cause mortality in adults with sepsis.” No secondary or safety outcome differed significantly between groups either.

Earlier critical-care work includes an earlier severe sepsis trial Wu 2013 - Wu J, Zhou L, Liu J et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013;17(1):R8. (opens PubMed in a new tab) and a trial of immune enhancement in predicted severe acute necrotising pancreatitis Ke 2022 - Ke L, Zhou J, Mao W et al. Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial. Intensive Care Med. 2022;48(7):899-909. (opens PubMed in a new tab). The hepatitis literature, where the medicine has its classic licensed use, includes work combining it with interferon alfa You 2006 - You J, Zhuang L, Cheng HY et al. Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study. World J Gastroenterol. 2006;12(41):6715-21. (opens PubMed in a new tab).

The gap between the evidence and the pitch

Read the settings again: sepsis. Necrotising pancreatitis. Chronic hepatitis.

These are people in hospital, often in intensive care, whose immune systems are failing under enormous acute stress. Thymosin alpha-1 is being investigated as a way to modulate that.

It is sold online to healthy adults who would like to get fewer colds. There is no trial of that, and the trials that do exist do not transfer to it — a drug that fails to reduce mortality in sepsis has told you nothing about your winter.

Status depends on where you are

US legal status - Research use only · not for human use

Thymosin alpha-1 is not FDA-approved. It holds marketing approval in a number of other countries, where it is a licensed prescription medicine rather than a research chemical. We are verifying the specific national approvals against primary regulators before naming them here.

This is the compound that most clearly justifies recording legal status country by country rather than as one global fact. “Thymosin alpha-1 is an approved medicine” and “thymosin alpha-1 is not approved” are both true statements, and which one governs you is a matter of geography.

Vendors quote the first and omit the second.

References

Bibliographic detail is fetched from PubMed, not written by us - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than our judgement.